New preclinical findings from extensive cell and animal studies suggest that a drug already used for a rare kidney disease could benefit patients with some mitochondrial disorders -- complex conditions with severe energy deficiency for which no proven effective treatments exist. Future clinical research is needed to explore whether the drug, cysteamine bitartrate, will meaningfully benefit patients.
from Top Health News -- ScienceDaily https://ift.tt/2Ua8jKo
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
During the Great Depression, Texans were put to work as fossil hunters. The workers retrieved tens of thousands of specimens that have been ...
-
Heart failure patients who consume more dietary fiber tend to have healthier gut bacteria, which is associated with reduced risk of death or...
-
The IT major further said the Ebit margin for the current quarter is expected to be between 20.5-21 per cent from Home Page https://ift.tt...
No comments:
Post a Comment